Turn Therapeutics Inc (TTRX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$9.80-2.68%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TTRX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of — · Company calendar date is not available
TTRX — earnings miss
Dated 2026-08-12
of this Current Report on Form 8-K and the Press Release furnished as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Why it matters: Topline results will show how well GX-03 treats atopic dermatitis. This may affect future plans.
Supportive ifTopline results from the Phase 2 trial are reported in Q4 2026.
Worry ifTopline results are delayed past Q4 2026.
Why it matters: If revenue growth speeds up, it signals a healthier environment for Turn Therapeutics.
Supportive ifThree-year revenue growth in the health care sector rises above 12%.
Worry ifThree-year revenue growth remains below 10%.
Why it matters: Cash updates will show if the company can keep running and fund trials.
Worry ifCash and cash equivalents are enough to fund operations until Q3 2027.
Less concerning ifCash position falls a lot. This may mean funding issues.
Why it matters: Updates on funding will show if Turn Therapeutics can keep its programs running.
Supportive ifThere is news of more funding from Avenue Capital due to clinical milestones.
Worry ifThere is no news or delays in getting the last $18 million from the capital facility.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$299 on $10,000 · ±3.0% | How much price usually moves either way. |
| Bad day | $931 loss on $10,000 · 9.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,054 loss on $10,000 · 70.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Updates on cash flow and runway are key for funding clinical trials and operations.
Worry ifManagement confirms cash runway extends beyond Q3 2027.
Less concerning ifManagement says cash runway is shorter than expected. This raises funding concerns.
Why it matters: Getting more funding is key for moving clinical programs forward and managing cash flow.
Supportive ifTurn Therapeutics announces it has secured more funding beyond the first $7 million.
Worry ifNo more funding is secured. This raises worries about cash flow and operations.
Why it matters: Earnings results can show if Turn is managing well in a tough sector.
Watch forEarnings report shows revenue growth higher than 5% year over year.
Also watch forEarnings report shows revenue growth lower than 0% year over year.
Why it matters: Expanding the trial could increase the potential market for GX-03. It may also indicate confidence in the product's efficacy.
Supportive ifThey announced wider enrollment rules for the GX-03 Phase 2 trial.
Worry ifThere was no news about expanding or limiting enrollment rules.
Why it matters: Better cash flow helps manage losses. It shows the company is healthier financially.
Supportive ifManagement plans to reach positive cash flow in the next two quarters.
Worry ifNo plan is announced, or cash flow continues to decline.
Why it matters: Interim results will indicate if the trial should continue as designed or expand enrollment. This affects future study direction.
Watch forAn independent committee says to keep going with the trial after good interim results.
Also watch forThe committee says to stop or change the trial because it is not effective enough.
Why it matters: Topline results will show how well GX-03 works for atopic dermatitis. This could impact future development and investor interest.
Supportive ifThe GX-03 Phase 2 trial shows better EASI scores than before.
Worry ifThe results show no clear improvement over the vehicle treatment.
Why it matters: Clear plans for spending money can help gain investor trust. This adds stability.
Watch forManagement will share a capital allocation plan in the next earnings call.
Also watch forThere is no news or unclear messages about spending money.
Why it matters: Finishing enrollment by year-end shows the trial is moving forward. It also hints at good results.
Supportive ifEnrollment for the Phase 2 trial of GX-03 reaches 120-135 patients by Q4 2026.
Worry ifEnrollment fails to reach the target of 120-135 patients by Q4 2026.
Why it matters: Updates on cash will show financial health. This affects the ability to fund trials.
Worry ifCash and cash equivalents remain above $10 million after Q4 2026.
Less concerning ifCash and cash equivalents fall below $8 million after Q4 2026.